https://doi.org/10.55788/0ce66e54
Using data from patients with axSpA confirmed by the Assessment of SpondyloArthritis international Society (ASAS) criteria, a retrospective study aimed to investigate whether distinct patterns of BMO distribution in the SIJ may be associated with specific demographic and/or clinical factors [1].
Between 2002 and 2024, 203 patients with axSpA who underwent SIJ MRI at Leeds Teaching Hospital were included. Participants had a mean age of 40.4 years, and 60.1% were men. BMO was found in 80.8%, 72.4% were positive for the HLA-B27 antigen, and nearly 60% had radiographic sacroiliitis. Moreover, 20.3% had psoriasis and 19.7% had uveitis.
The Leeds axSpA MRI Scoring system scores BMO in each SIJ quadrant (upper or lower sacral and upper or lower iliac) from 1 to 3. Patients were grouped into 3 categories: 50 had predominant-upper (pU) BMO, 88 had predominant-lower (pL) BMO, and 26 had symmetrical upper-and-lower pattern.
Table: Disease-related factors associated with BMO localisation in SIJ [1]

BMO, bone marrow oedema; M/F, male/female; MRI, magnetic resonance imaging; SD, standard deviation.
Comparing the 2 non-symmetrical groups revealed differences in clinical features. The pU group was older (42.6 vs 35.8; P=0.002), had higher body mass index (30.3 vs 26.2; P=0.005), longer disease duration (5.8 years vs 2; P=0.002), lower HLA-B27 positivity (54% vs 80.2%; P=0.001), more frequent concomitant psoriasis (38.8% vs 13.6%; P<0.001) and less common uveitis (12% vs 28.4%; P=0.026) compared to the pL group. Other interesting, but not statistically significant, results of the comparison between pU BMO and pL BMO arms included the proportion of men (56% vs 68.2%; P=0.15) and the mean CRP levels (11.6 vs 15.4 mg/L; P=0.263).
Several disease-related factors were associated with the regional BMO types (see Table). The upper SIJ BMO scores were positively associated with body mass index (P<0.001) and inversely with uveitis (P<0.001). In the lower combined SIJ BMO scores, significant associations included younger age (P=0.005) and HLA-B27 positivity (P=0.002).
The investigators concluded that the topographic differences in BMO may reflect divergent biomechanical and inflammatory pathways converging on the SIJ. Recognising these patterns may enhance phenotypic stratification and inform future studies aimed at personalised management in axSpA.
- Abacar K, et Two distinct patterns of sacroiliac joint bone marrow oedema in axial spondyloarthritis are associated with HLA-B27 status, Body Mass Index and/ psoriasis. POS0126, EULAR 2025, 11–14 June, Barcelona, Spain.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Digital therapeutic Axia enhances outcomes in axial spondyloarthritis Next Article
Robust renal efficacy with obinutuzumab across key clinical criteria in lupus nephritis »
« Digital therapeutic Axia enhances outcomes in axial spondyloarthritis Next Article
Robust renal efficacy with obinutuzumab across key clinical criteria in lupus nephritis »
Table of Contents: EULAR 2025
Featured articles
A novel compound emerging as a treatment for refractory gout
Osteoarthritis and Osteoporosis
Initiating glucocorticoids for rheumatic diseases: sequential romosozumab- denosumab treatment increases lumbar BMD
Rapid and clinically meaningful pain relief in knee OA with novel neurotrophin inhibitor
Best of the Posters
Air pollution may increase autoimmune risk through ANA positivity
Weight-bearing exercise contributes to bone health in inflammatory rheumatic diseases
Late-Breaking Abstracts
Combination of leflunomide and hydroxychloroquine reduces disease activity in Sjögren’s disease
Guselkumab slows joint damage progression in PsA
Deucravacitinib shows robust 16-week efficacy in biologic-naïve PsA participants
Arthritis in 2025
Preventive abatacept may delay RA diagnosis in at-risk populations
Patients with musculoskeletal pain and ACPA positivity: most progress to arthritis, but not always RA
Spotlight on Spondyloarthritis
Bone marrow oedema in axial spondyloarthritis: different patterns identified
Digital therapeutic Axia enhances outcomes in axial spondyloarthritis
What is New in Lupus, Scleroderma, and Myositis
Combination of rituximab and mycophenolate mofetil offers no superiority over monotherapy in SSc-related ILD
Early clinical events flag systemic sclerosis earlier than the classification criteria
New targeted therapy shows efficacy in inflammatory myopathy
Enpatoran shows encouraging signals in lupus, despite an unmet primary endpoint
Robust renal efficacy with obinutuzumab across key clinical criteria in lupus nephritis
New Developments in Crystal-related Disorders
Targeting serum uric acid pays off: gout strategy cuts MACE
A novel compound emerging as a treatment for refractory gout
Related Articles
July 31, 2023
PsA patients: highest risk of developing NAFLD
January 18, 2022
Zinc may worsen rheumatoid arthritis, lab study suggests
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
